Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.
Clinical trial NCT01868048 · WITHDRAWN
Trial details
- NCT number
- NCT01868048
- Sponsor
- GW Research Ltd
- Status
- WITHDRAWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Primary completion
- 2017-06-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.